Kenneth R Chapman

Prof. Dr. Kenneth R Chapman

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in European Respiratory Journal
Verified
Journal Article
Closed access
KCKenneth R Chapman
Kenneth R Chapman
MMMarc Miravitlles
Marc Miravitlles
DMD. M. Mannino
D. M. Mannino
JSJoan B Soriano
Joan B Soriano
PVP. A. Vermeire
P. A. Vermeire
RBR. Beasley
R. Beasley

1 July 2015 in The Lancet
Verified
Journal Article
Closed access
KCKenneth R Chapman
Kenneth R Chapman
JBJonathan G W Burdon
Jonathan G W Burdon
EPEeva Piitulainen
Eeva Piitulainen
RSRobert A Sandhaus
Robert A Sandhaus
NSNiels Seersholm
Niels Seersholm
NMNoel G McElvaney
Noel G McElvaney

24 October 2007 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
KCKenneth R Chapman
Kenneth R Chapman
LBL. P. Boulet
L. P. Boulet
RRR. M. Rea
R. M. Rea
EFE. Franssen
E. Franssen
Telephone surveys describing suboptimal asthma control may be biased by low response rates.In order to obtain an unbiased assessment of asthma control and assess its impact in primary care, primary care physicians used a 1-page control questionnaire in 50 consecutive asthma patients.Of the 10,428 patients assessed by 354 physicians, 59% were uncontrolled, 19% well-controlled and 23% totally controlled. Physicians overestimated control, regarding only 42% of patients as uncontrolled. Physicians were more likely to report plans to alter the regimens of uncontrolled patients than controlled patients (1.29versus0.20 medication changes per patient) doing so in a fashion consistent with guideline recommendations. Of the uncontrolled patients, 59% required one or more urgent care or specialist visitsversus26 and 15% of well-controlled or totally controlled patients, respectively. Patients were more likely to report short-term symptom control when they had not required urgent or specialist care (odds ratio 5.68; 95% confidence interval 4.91–6.58).The majority of asthma patients treated in general practice are uncontrolled. Lack of control can be recognised by physicians who are likely to consider appropriate changes to therapy. A lack of short-term symptom control of asthma is associated with excess healthcare utilisation.

1 September 2013 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
MDMarc L Decramer
Marc L Decramer
KCKenneth R Chapman
Kenneth R Chapman
RDRonald Dahl
Ronald Dahl
PFPeter Frith
Peter Frith
GDGilles Devouassoux
Gilles Devouassoux
DMDanny McBryan
Danny McBryan

20 March 2012 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
PDF file
JBJean Bourbeau
Jean Bourbeau
WTWan C. Tan
Wan C. Tan
ABAndrea Benedetti
Andrea Benedetti
SAShawn D. Aaron
Shawn D. Aaron
KCKenneth R Chapman
Kenneth R Chapman
FGfor the CanCOLD study group
for the CanCOLD study group
Awareness, diagnosis and treatment of COPD, compared to other major causes of death, remains far too low. This article describes the protocol objectives, design and the approaches taken in the Canadian Chronic Obstructive Lung Disease (CanCOLD) study, an epidemiological and integrated research. The CanCOLD study aims at better understanding heterogeneity of COPD presentation and disease progression. We hypothesize that individuals with unfavourable COPD “phenotypes” and subjects at-risk (ever smokers) with unhealthy lifestyle habits, environmental/work exposure, or co-morbidities will have increased risk of lung function decline independent of their cumulative exposure to cigarette smoke. The study is a prospective multi-center cohort study (9 sites in 6 provinces) built on the Canadian COPD prevalence study “COLD.” The study plan is to include 1800 subjects at least 40 years old who were sampled from the general population and who were found to fall within 4 groups: 1) COPD moderate–severe (GOLD 2–4); 2) COPD mild (GOLD 1); 3) subjects at-risk (ever smoker); and, 4) subjects never-smoker free of airflow obstruction. Data collection is based on using strictly standardized methods involving questionnaires, pulmonary function and cardiorespiratory exercise tests, CT scans, and blood sampling. CanCOLD is a unique study that will address challenging and important research questions on COPD disease evolution and disease management and will help to define the natural history of COPD disease evolution in individuals at-risk for COPD and in those with COPD who have mild disease.

1 January 2009 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
KCKenneth R Chapman
Kenneth R Chapman
RSRobert A. Stockley
Robert A. Stockley
CDClara Dawkins
Clara Dawkins
MWMahlon M. Wilkes
Mahlon M. Wilkes
RNRoberta J. Navickis
Roberta J. Navickis
Augmentation with exogenous alpha1-antitrypsin (alpha1-AT) is the only specific therapy for alpha1-AT deficiency. Uncertainty persists concerning its effectiveness. To test the hypothesis that augmentation therapy in patients with alpha1-AT deficiency slows the decline in FEV1. Randomized and nonrandomized clinical studies with either parallel-group design or single cohort pre-post design were eligible if they compared augmentation therapy with a control regimen and if long-term (> 1 y) longitudinal FEV1 follow-up data were collected. FEV1 data from five trials with 1509 patients were combined by random effects meta-analysis. The decline in FEV1 was slower by 23% (absolute difference, 13.4 ml/year; CI, 1.5 to 25.3 ml/year) among all patients receiving augmentation therapy. This overall protective effect reflected predominantly the results in the subset of patients with baseline FEV1 30-65% of predicted. In that subset, augmentation was associated with a 26% reduction in rate of FEV1 decline (absolute difference, 17.9 ml/year; CI, 9.6 to 26.1 ml/year). Similar trends amongst patients with baseline FEV1 percent of predicted < 30% or > 65% were not statistically significant. This meta-analysis supports the conclusion that augmentation can slow lung function decline in patients with AAT deficiency Patients with moderate obstruction are most likely to benefit.